A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 897,603 shares of PSTX stock, worth $2.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
897,603
Previous 854,900 5.0%
Holding current value
$2.57 Million
Previous $2.5 Million 2.84%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.7 - $4.04 $115,298 - $172,520
42,703 Added 5.0%
897,603 $2.57 Million
Q2 2024

Aug 09, 2024

BUY
$2.0 - $3.46 $595,000 - $1.03 Million
297,500 Added 53.37%
854,900 $2.5 Million
Q1 2024

May 13, 2024

BUY
$2.76 - $4.13 $75,348 - $112,749
27,300 Added 5.15%
557,400 $1.78 Million
Q4 2023

Feb 13, 2024

SELL
$1.83 - $3.51 $462,936 - $887,928
-252,971 Reduced 32.3%
530,100 $1.78 Million
Q3 2023

Nov 14, 2023

BUY
$1.62 - $2.79 $393,736 - $678,101
243,047 Added 45.01%
783,071 $1.86 Million
Q2 2023

Aug 11, 2023

SELL
$1.66 - $3.4 $104,872 - $214,798
-63,176 Reduced 10.47%
540,024 $950,000
Q1 2023

May 12, 2023

BUY
$3.08 - $8.73 $1.25 Million - $3.55 Million
406,900 Added 207.28%
603,200 $1.86 Million
Q4 2022

Feb 13, 2023

SELL
$3.33 - $6.38 $489,510 - $937,860
-147,000 Reduced 42.82%
196,300 $1.04 Million
Q3 2022

Nov 14, 2022

SELL
$2.43 - $4.51 $89,424 - $165,968
-36,800 Reduced 9.68%
343,300 $1.21 Million
Q2 2022

Aug 12, 2022

BUY
$1.87 - $5.0 $361,097 - $965,500
193,100 Added 103.26%
380,100 $981,000
Q1 2022

May 13, 2022

BUY
$3.22 - $7.04 $493,948 - $1.08 Million
153,400 Added 456.55%
187,000 $838,000
Q4 2021

Feb 11, 2022

BUY
$6.23 - $7.6 $128,961 - $157,320
20,700 Added 160.47%
33,600 $229,000
Q3 2021

Nov 12, 2021

BUY
$7.09 - $10.71 $91,461 - $138,159
12,900 New
12,900 $94,000

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $245M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.